Rats with nephrotic syndrome (NS) have a fivefold increase in lipids and a similar decrease in triglyceride-rich lipoprotein (TRL) clearance. Lipoprotein lipase (LPL) is reduced both in NS and in the Nagase analbuminemic rat. These rats have nearly normal triglyceride levels and TRL clearance, suggesting that reduction in LPL alone is insufficient to cause increased TRL levels. Apolipoprotein E (apoE) was decreased in lipoprotein fractions in NS, but not in analbuminemia. Here we tested whether decreased apoE binding to lipoproteins in NS contributes to hyperlipidemia by decreasing their affinity for lipoprotein receptors. Plasma apoE was increased 60% in both NS and analbuminemia compared with control (CTRL) as a result of a 60% decreased apoE clearance. Very-low-density lipoprotein and highdensity lipoprotein in NS had significantly less apoE per mole of phospholipid compared with analbuminemia or CTRL and significantly greater lipid content; however, apoE binding did not differ by lipoprotein class or group. There was a significant reduction of receptors for lipoproteins in nearly all tissues in NS compared with CTRL and analbuminemia. Thus, apoE within lipoprotein fractions was reduced by dilution resulting from expansion of the lipid fraction due to decreased lipolysis and not to differing affinity for apoE. Decreased lipoprotein receptors result from proteinuria and contribute to hyperlipidemia in NS. 1,2 One initial step in clearance involves engagement with lipoprotein lipase (LPL) tethered to vascular endothelial cells that is decreased as a consequence of decreased serum albumin levels, which result from urinary protein loss in NS, 3 but is due to a defect in albumin gene expression in the Nagase analbuminemic rat (NAR), with hereditary analbuminemia, and thus occurs in the absence of proteinuria.
Rats with nephrotic syndrome (NS) have a fivefold increase in lipids and a similar decrease in triglyceride-rich lipoprotein (TRL) clearance. Lipoprotein lipase (LPL) is reduced both in NS and in the Nagase analbuminemic rat. These rats have nearly normal triglyceride levels and TRL clearance, suggesting that reduction in LPL alone is insufficient to cause increased TRL levels. Apolipoprotein E (apoE) was decreased in lipoprotein fractions in NS, but not in analbuminemia. Here we tested whether decreased apoE binding to lipoproteins in NS contributes to hyperlipidemia by decreasing their affinity for lipoprotein receptors. Plasma apoE was increased 60% in both NS and analbuminemia compared with control (CTRL) as a result of a 60% decreased apoE clearance. Very-low-density lipoprotein and highdensity lipoprotein in NS had significantly less apoE per mole of phospholipid compared with analbuminemia or CTRL and significantly greater lipid content; however, apoE binding did not differ by lipoprotein class or group. There was a significant reduction of receptors for lipoproteins in nearly all tissues in NS compared with CTRL and analbuminemia. Thus, apoE within lipoprotein fractions was reduced by dilution resulting from expansion of the lipid fraction due to decreased lipolysis and not to differing affinity for apoE. Decreased lipoprotein receptors result from proteinuria and contribute to hyperlipidemia in NS. The nephrotic syndrome (NS) is a consequence of urinary protein loss and is characterized by hypoalbuminemia and increased blood lipid levels. Increased levels of triglyceriderich lipoproteins (TRLs) consisting of very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein results almost entirely from decreased clearance.
1,2 One initial step in clearance involves engagement with lipoprotein lipase (LPL) tethered to vascular endothelial cells that is decreased as a consequence of decreased serum albumin levels, which result from urinary protein loss in NS, 3 but is due to a defect in albumin gene expression in the Nagase analbuminemic rat (NAR), with hereditary analbuminemia, and thus occurs in the absence of proteinuria. 4 Endothelialbound LPL is thus reduced to a greater extent in NAR than in NS, 5 yet clearance of both chylomicrons and VLDL are normal or nearly so in these animals, and triglyceride (TG) levels are only marginally increased, 6 suggesting that a defect, beyond LPL depletion, resulting in some undefined way from proteinuria, contributes to defective lipoprotein clearance in proteinuric organisms. The structure of both high-density lipoprotein (HDL) and VLDL in NS differs from that observed both in controls (CTRL) and NAR. The primary structural difference we reported was that VLDL and HDL from NS was depleted of apolipoprotein E (apoE), whereas both HDL and VLDL from the NAR were enriched in apoE. [6] [7] [8] ApoE engages LPL allowing for more effective binding of these proteins with the enzyme that initiates lipolysis, and addition of apoE to VLDL obtained from nephrotic animals increased lipolysis in vitro. 6, 7 We thus hypothesized that proteinuria altered the affinity for HDL and VLDL; decreased apoE binding to lipoproteins in NS may contribute to hyperlipidemia by decreasing its affinity for lipoprotein receptors.
Lipoprotein receptors have an important role in the clearance of TRLs and tissue uptake. [9] [10] [11] [12] [13] [14] Multiple receptors mediate clearance of TRLs; the low-density lipoprotein receptor (LDLR) binds to apoB and apoE, while VLDL receptor (VLDLR) and the low-density lipoprotein receptor-related protein (LRP) bind apoE. In addition to their different binding ligands, LDLR, VLDLR, and LRP have different tissue distributions. 15 LDLR and LRP are mainly found in the liver, and VLDLR is primarily expressed in the heart, skeletal muscles, adipose tissue, and brain. LDLR and VLDLR have been shown to be decreased in muscle and heart in nephrotic rats; [16] [17] [18] however, it is unknown as to what the tissue distribution of these receptors is in the NAR. Recent studies have also shown that glycosylphosphatidylinositol anchored HDL-binding protein 1 (GPIHBP1), an endothelial cell-surface glycoprotein that binds LPL and is required for the lipolysis of TRLs. [19] [20] [21] It is unknown whether GPIHBP1 is altered in NS and NAR, a defect that could amplify or efface the effect of LPL depletion characteristic of hypoalbuminemic states.
We conducted this study for three purposes: (1) to establish the determinants of apoE levels in NS rats and NAR in comparison with CTRL; (2) to establish the redistribution of apoE within the lipoprotein fractions resulted from altered affinity of apoE for different lipoprotein fractions in the different models; and (3) to establish whether protein and receptor density might be altered differently in NS and NAR affecting tissue lipoprotein uptake and distinguishing the effects of hypoalbuminemia in the presence and absence of proteinuria.
RESULTS

Measurement of distribution of apoE, composition, and particle size in lipoprotein fractions
The plasma concentration of apoE was significantly greater in both NAR and NS compared with CTRL, but did not differ between NAR and NS (Table 1) . Plasma TG, cholesterol, and phospholipids (PLs) were all significantly greater (Po0.05) in NS than in NAR and CTRL (Table 1) . However, plasma TG and cholesterol concentrations in the NAR were slightly but significantly greater (Po0.05) than CTRL.
Characterization of lipoprotein composition. In all three lipoprotein classes, the ApoE/PL ratio was greater in the lipoprotein fraction from CTRL and lowest in the lipoproteins from NS. By contrast, lipid content was lowest in CTRL. Cholesterol content of lipoprotein fractions from CTRL was significantly lower and was greatest in NS (Table 2) . Similarly, TG content was greatest in VLDL and low-density lipoprotein (LDL) from NS, intermediate in the NAR, and also lowest in CTRL. Thus, lipoproteins from NS were depleted of apoE and enriched in core lipids (cholesterol and TG) per mole of PLs, representing a measure of available lipoprotein surface area (Table 2) . ApoE/PL ratio in VLDL was over 15-fold lower in NS than in CTRL, and over 3-fold lower in the NAR (Table 2 ). There was also a significant decrease of apoE/ PL ratio in HDL in NS than in CTRL and NAR. By contrast, the apoB/PL and apoC/PL ratios were no different in any of the lipoprotein classes between CTRL, NS, and NAR.
Lipoprotein size distribution. Particle diameter of VLDL from plasma showed marked heterogeneity among the three groups of rats. Plasma VLDL particles from both NS and NAR were larger than CTRL (Figure 1a ). There was no significant difference in the size distribution of LDL particles among the three groups (Figure 1b) . HDL diameters in the NARs were significantly (Po0.05) smaller than those of both NS and CTRL (Figure 1c ). ApoE clearance and absolute turnover rate in HN, NAR, and CTRL ApoE clearance was significantly greater in CTRL animals (1.50 ± 0.15 ml/100 g body weight/h) than either NS (0.87 ± 0.15 ml/100 g body weight/h) or NAR (0.94 ± 0.12 ml/100 g body weight/hr) ( Table 3) . The difference in clearance between NAR and NS was not significant. At steady state, the product of apoE concentration and clearance is total apoE absolute catabolic rate per unit time and is equal to apoE synthetic rate at steady state. ApoE absolute catabolic rate was not different among the experimental groups (Table 3) . Thus, the difference in plasma concentrations between the three groups was entirely a consequence of differences in apoE clearance with no difference in apoE synthetic rate.
Binding of apoE to lipoprotein fractions
The C-terminal region of apoE has been identified as the protein's principal lipid-binding domain. [22] [23] [24] As shown previously, 25, 26 a decrease in the self-association of lipid-free apoE protein is observed via the decreased broadening of the electron paramagnetic resonance (EPR) spectrum resulting from a diminished magnetic coupling between spin labels attached to position Trp264 in the C-terminal domain of the protein. Upon lipid binding, the self-association of the Cterminal domain is disrupted, resulting in larger EPR amplitude due to the decreased dipolar broadening. A typical response of the spin-labeled apoE 4 -W264C as a function of VLDL is shown in Figure 2 . The apoE 4 isoform is chosen because of the absence of additional cysteine moieties in regions of the protein that do not engage in lipid binding, thus interfering with the measurement of changes in the region of interest. Each sample contains the identical amount of spin-labeled apoE 4 ; however, the lipid-free sample (black trace) displays the maximum amount of spectral broadening. The loss of broadening is dependent on the amount of VLDL added, with VLDL at 0.64 mg/ml PL (blue trace) inducing a much greater change than does a lower concentration of VLDL with the same concentration of label (red trace).
With lipoprotein concentration serial dilution (log order), we found that apoE bound to all particles in a saturable manner. There was no significant difference in apoE binding to VLDL, LDL, and HDL obtained from CTRL and NS (Table 4) . No significant difference in binding affinity was found either by lipoprotein type (HDL, LDL, and VLDL), or between NS and CTRL animals ( Figure 3 and Table 4 ).
Measurement of tissue lipoprotein receptors and GPIHBP1
VLDL receptors expressed in the liver, heart, muscle, and adipose tissue from NS were significantly decreased compared with CTRL or NAR (Figure 4 ). There was a relative abundance of VLDLR in the NAR compared with CTRL. Hepatic LDLR was decreased in NS compared with CTRL and NAR; however, this was not the case in the heart. There was significantly less abundance of heart LDLR in the NAR than in NS and CTRL. GPIHBP1 in red muscle was significantly reduced in NS compared with both CTRL and NAR, but no difference was observed between CTRL and NAR. In contrast, this receptor in the heart was significantly reduced in both NS and NAR. No significant difference of hepatic LRP was found among groups.
DISCUSSION
The primary process that causes increased lipid levels, especially TG levels, is decreased clearance. 3, 27 It has been established that there is both depletion of LPL and abnormal distribution of apoE in lipoprotein classes 28, 29 in NS; however, LPL is also reduced in the NAR, and these animals have limited increase in lipid levels. Clearance of TRL is reduced by approximately an order of magnitude in NS and is essentially normal in the NAR, explaining their nearly normal levels of TRLs. 3, 16, 25 In this study, we find that apoE levels in plasma are increased B60% in NS accompanied by a reduction in apoE clearance of B60%. By contrast, TG levels are increased Bfivefold in NS compared with CTRL, 4 to lipoproteins isolated from control and nephrotic syndrome (NS) rats. Spin-labeled apolipoprotein E-4 (apoE 4 ) (final protein concentration 0.5 mg/ml) incubated with very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and highdensity lipoprotein (HDL) isolated from control and NS rats at increased dose of phospholipid (PL) concentration overnight at 4 1C. The binding was measured by broadening of the electron paramagnetic resonance spectrum of spin-labeled apoE by increasing concentrations of lipoproteins. The curve was estimated by nonlinear regression.
suggesting that there is a mismatch in the relative defect in apoE clearance and this mismatch affects the final distribution of apoE within the apoE and TRL, diluting apoE on the surface, measured by PLs. There was no difference in apoE affinity or maximum binding capacity of any of the lipoproteins. The differences in apoE content of each lipoprotein subclass were a consequence of apoE availability and lipoprotein surface area available for binding. Although , and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) in the liver, heart, muscle, and adipose tissues of the control, nephrotic syndrome (NS), and Nagase analbuminemic rats (NARs). The relative density of the liver, heart, muscle, and adipose LDLR (a), VLDLR (b), LRP (c), and GPIHBP1 (d) mass in NS and NA rats compared with the controls. Representative western blot of the liver, heart, muscle, and adipose LDLR, VLDLR, LRP, and GPIHBP1 versus glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from control, NS, and NARs. Tissue lysates were separated on 4-20% sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotted with anti-GAPDH, anti-LDLR, anti-VLDLR, anti-LRP, and anti-GPIHBP1. Values represent the mean ± s.e.m. of six rats.
apoE may serve as a ligand for lipoprotein receptors, the observed difference in lipoprotein apoE levels is unlikely to be the primary determinant for defective lipoprotein removal, but instead likely results from greatly impaired clearance of lipids relative to the reduction in clearance of apoE. ApoE, an exchangeable component of TRL and HDL, has a key role in TRL clearance and cholesterol homoeostasis. ApoE modulates plasma and cellular cholesterol levels by its ability to (1) act as a ligand for the LDL receptor family 30 and heparin sulfate proteoglycans, 31 which leads to cellular uptake and clearance of TRL remnant lipoprotein particles, and (2) promote cholesterol efflux from peripheral tissues to nascent HDL particles in atherosclerotic lesions. 32 It is known that TRLs are cleared via apoE-mediated clearance pathways including receptor-dependent (e.g., LDLR, LRP, and VLDLR) and receptor-independent pathways (heparin sulfate proteoglycans 33, 34 and the scavenger receptor class B type I. [35] [36] [37] In this study, we found that a 60% increase of apoE concentration in NS was accompanied by a 60% reduction in clearance without the difference of apoE turnover rate among the NS, NAR, and CTRL groups. Our previous study showed that apoE mRNA was not increased in either NS or NAR, 28 consistent with the current observation. These studies suggested that the increase in plasma apoE concentration in NS is a consequence of a reduced clearance with no difference in apoE synthesis. The increased VLDL particle size also indicated that the defect is in bulk particle removal rather than lipolysis of particles per se, and thus the increase in surface area is a consequence of more apoEpoor particles.
There was no significant difference in lipoprotein binding to apoE among the groups. Thus, altered apoE-binding affinity is unlikely to be the cause of the observed apoE distribution within lipoprotein classes in NS.
Several steps occur during TRL clearance. First, circulating TRLs bind to LPL and other proteins that have a role in lipoprotein clearance. Second, TRLs interact with LPL, which hydrolyzes TG, and produce TRL remnants. Third, the liver Decreased apolipoprotein E is not related to binding affinity o r i g i n a l a r t i c l e removes remnants via TRL apoE or apoB binding to receptors. The primary difference between NS and both NAR and CTRL is a significant reduction in the presence of LDLR, VLDLR, and LRP in virtually all tissues except the heart. Indeed, the VLDLR was significantly increased in the NAR. These receptors may facilitate the removal of TRLs and partially explain the near-normal removal of them in the NAR despite decreased LPL. A recent study has shown that an endothelial cell protein, GPIHBP1, is required for the lipolysis of TRL via the binding to LPL. 38, 39 GPIHBP1 is located within the lumen of capillaries of the heart, skeletal muscle, and adipose tissue. 38 In the current study, we found that there was significantly lower expression of red muscle GPIHBP1 in NS compared with the CTRL and NAR. Heart GPIHBP1 in NS or NAR was significantly less than that in CTRL, which is consistent with the lower expression of LPL in NS and NAR. Heart GPIHBP1 was significantly greater in NAR than NS. Our result is consistent with the recent study from the Vaziri group 40 that demonstrated GPIHBP1 deficiency in skeletal muscle, adipose tissue, and myocardium in rats with chronic kidney disease with proteinuria.
ApoE acts as a receptor-binding ligand at the surface of TRLs. The degree of exposure of apoE at the surface of TRLs and its affinity for the receptor both determine the uptake and catabolism of these lipoproteins. ApoE and/or apoB contribute to the interaction of lipoproteins with several cellular receptors. The degree of exposure of apoE at the surface of normo-and hyperlipidemic VLDL can modulate their uptake by the receptors. Normolipidemic VLDL is poorly recognized by the LDLR, whereas hypertriglyceridemic VLDLs are cleared more efficiently through this pathway. Our receptor data showed a significant reduction in LDLR and VLDLR in NS tissues, which is consistent with the previous study, 41 whereas we found that receptors in the NAR tissues were similar to the CTRL tissues, which may explain the nearly normal clearance of TRL in the NAR, suggesting that the principal differences observed in TRL clearance between NS and CTRL are a consequence of reduction in receptor density rather than affected by either LPL or apoE concentration on lipoproteins.
The mechanism of hyperlipidemia in NS is a very complicated process that involves many proteins, lipids, and other structures, as well as multiple pathways. In addition to the GPIHBP1, LPL, VLDLR, LDLR, and LRP, hepatic TG lipase has a major role in clearance of TGs and PLs in intermediate-density lipoprotein and HDL particles. The Vaziri group has demonstrated a significant reduction of hepatic TG lipase expression and activity in animals with puromycin aminonucleoside-induced NS and Imai rats with spontaneous glomerulosclerosis. [42] [43] [44] The same group has also demonstrated that downregulation of hepatic HDL receptor, SRB1, in NS contributes to the associated dyslipidemia and elevation of the lipid contents of HDL, and that LCAT deficiency caused by its urinary losses in NS contributes to alteration of the HDL structure. 45, 46 In summary, the apoE pool size is increased but diluted within the lipoprotein classes by processes not related to apoE binding, but possibly a consequence of a greater quantitative defect in removal of lipids from lipoproteins than of apoE. Reduced lipoprotein receptors and GPIHBP1 might contribute to the hyperlipidemia in NS, but the mechanism by which proteinuria affects lipoprotein receptors is unclear.
MATERIALS AND METHODS
All procedures involving animals were approved by the Animal Review Committee at the University of California Davis and the Department of Veterans Affairs.
Protocol 1: Measurement of distribution of apoE within lipoprotein fractions, lipoprotein composition, and particle size Male Sprague-Dawley rats (150 g) were obtained from Simonson Farms (Hayward, CA) for CTRL animals and for experiments in which the NS was induced. The NARs were obtained from our own breeding colony maintained at the University of California Davis (Davis, CA) as described previously 47 and are on a Sprague-Dawley background. All animals were kept in 24-h light/dark rooms and fed Purina Purified Protein diet 5755 (LabDiet, St Louis, MO). These studies were conducted in five CTRL, six NS, and five NARs. NS was induced by intraperitoneal injection with sheep anti-FX1a serum to induce proteinuria. The antibody was a gift from Dr William Couser (Seattle, WA). Urinary albumin excretion was determined 2 weeks following injection of FX1A, and rats with albuminuria of 4300 mg/day were selected. Blood was obtained from a tail vein following an overnight fast to establish baseline lipid levels. Rats were anesthetized with an intraperitoneal injection of 75 mg/kg (CTRL) or 40 mg/kg (NS and NAR) sodium pentobarbital and were then killed by aortic puncture and exsanguination to obtain blood for lipoprotein purification.
Lipoprotein isolation and characterization. Lipoproteins were subfractionated from ethylenediaminetetraacetic acid plasma according to their hydrated density by sequential density-gradient ultracentrifugation. 48 Plasma lipids and lipoprotein composition analyses. TG concentration was determined enzymatically (Sigma Chemical, St Louis, MO). Total cholesterol and PL levels were measured using enzymatic kits (WAKO, Richmond, VA).
Analysis of lipoprotein fraction particle size. VLDL diameters were measured by dynamic laser light scattering (Microtrac series 250 ultrafine particle analyzer with a laser probe tip (UPA-250; Microtrac, Clearwater, FL)) and the Microtrac software (Honeywell, Washington, PA) as described in Wang et al. [49] [50] [51] The results of primary data collection can be expressed as a distribution of particle area. 52 Raw particle diameter distributions were converted to population percentiles in order to facilitate statistical comparisons. LDL and HDL particle size were measured using non-denaturing gradient gel electrophoresis. 53, 54 Migration of lipoproteins in gel was measured using an Odyssey imager and software (LI-COR, Lincoln, NE). Calibration curves for LDL proteins were constructed by plotting the logarithm of particle diameter against the distance migrated relative to that of Rf (abscissa). Particle sizes were calibrated by comparison with migration distances of standard proteins of known diameter. 55 Enzyme-linked immunosorbent assay for ApoE. For measurement of apoE in plasma and lipoprotein fractions, 100 ml affinity-purified goat anti-rat apoE antibody (custom prepared) prepared in 0.1 M sodium bicarbonate was applied to 96-well enzyme-linked immunosorbent assay plates (NUNC, Rochester, NY) at a concentration of 20 mg/ml, with incubation at 4 1C overnight. ApoE antibody and IgG HRP were obtained from Pierce (Rockford, IL) Protocol 2: Measurement of apoE fractional catabolic rate in NS, NAR, and CTRL ApoE clearance was measured in seven CTRL, seven NS, and nine NARs.
Purification and radiolabeling of apoE. ApoE was isolated from the density fraction d41.019 g/ml obtained by ultracentrifugation from the plasma of female NAR. 56 Purified apoE was iodinated by a modification of the iodine monochloride method. I-labeled apoE was reassociated with apoE-containing VLDL particles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by phosphor imaging was used to ensure that all 125 I in the lipoproteins prepared for clearance study was contained only in apoE.
Measurement of apoE clearance. Blood was obtained after an overnight fast from a tail vein immediately before apoE injection to determine fasting TG, albumin, and apoE levels. A measure of 7 mg of VLDL 125 I-labeled with apoE, containing 1-2 Â 10 7 c.p.m. of 125 I, was injected as a bolus into the tail vein. The animals were lightly restrained but were not anesthetized. Blood samples of 150 ml were obtained from a tail vein at 5, 15, 30, 60 min, 2, 5, 10, 15, 22, 30, and 48 h following injection, and centrifuged to separate plasma from red cells. Three 10-ml aliquots of plasma at each time point were counted in a gamma counter (Perkin Elmer, Shelton, CT) for 10 min.
The plasma radioactivity disappearance curve was integrated by the use of the numerical model using SAAM II (SAAM Institute, Seattle, WA). Clearance is calculated as the dose injected/area under the disappearance curve. 56 Protocol 3: Measurement of binding of apoE in each lipoprotein fraction Animals. ApoE binding was measured in seven CTRL and seven NS rats. The animal resources, housing, and diet were the same as that in the protocol 1, except that animals were injected with adriamycin (5 mg/kg) (Adriamycin RDF: Pharmacia and Upjohn, Milan, Italy) in tail veins to induce NS.
ApoE binding to lipoprotein fractions by EPR spectroscopy. We measured binding of apoE to each lipoprotein fraction using spin-labeled apoE as a probe, to observe the protein's structure and dynamics by EPR spectroscopy. To generate the apoE probe, a site-directed nitroxide spin label was introduced into the C-terminal domain of human apoE 4 as described by Hatters et al. 57 Briefly, the gene encoding human apoE 4 containing the W264-4Cys (apoE 4 -W264C) mutation was expressed in Escherichia coli, purified, and labeled with the thio-reactive MTS-SL spin label (1-oxyl-2,2,5,5-tetramethyl-D3-pyrroline-3-methyl) methanethiosulfonate, 58 a kind gift from Prof. Kalman Hideg.
The spin-labeled apoE 4 (264C) (0.75 mg/ml protein in Trisbuffered saline) was incubated overnight at 4 1C with a sample containing saline, VLDL, LDL, or HDL. We performed a dose response of apoE-binding affinity with constant spin-labeled apoE (0.75 mg/ml protein) and increasing amounts of experimental lipoprotein at VLDL (PL: 0.0037, 0.0184, 0.092, 0.46, 2.3 mg/ml), LDL (PL: 0.07, 0.37, 1.84, 9.2 and 46 mg/ml), or HDL (PL: 0.09, 0.45, 2.24, 11.2, and 56 mg/ml). Samples were placed in quartz capillary tube and scanned by EPR. EPR measurements were recorded in a JEOL X-band spectrometer fit with a loop-gap resonator. 59 Spectra of samples were obtained by a 2-min scan over 400 G at a power of 2 mW and a modulation amplitude optimized to the natural line width (1.5-2.5 G) at room temperature as described. 59, 60 Data were normalized according to the same spin number, as calculated from the integrated intensities of the EPR spectra.
The concentration of the lipoprotein was increased over several log orders in order to establish B max and the point of half saturation. This experiment allowed us to establish both the binding capacity and affinity of each protein for apoE. The concentration of bound protein was calculated based on the measured spectrum. The apparent dissociation constant (KD) and maximum binding capacity (B max ) were estimated by nonlinear regression using the equation Y ¼ B max *X/(KD þ X). Data were processed and fitted using the GraphPad Prism software (GraphPad software, San Diego, CA).
Protocol 4: Measurement of tissue lipoprotein receptors and GPIHBP1
Tissue lipoprotein receptors were measured in six NS, six CTRL, and six NARs. The animal resources, housing, and diet were described as in protocol 1.
Tissue LDLR, VLDLR, LRP, and GPIHBP1 in rats were quantified by western blot analysis. Rat tissue plasma membranes were prepared according to the method of Vaziri et al. 41 Protein aliquots (50 mg) were detected by western blot analysis as described Western blot analysis was carried out according to standard protocols. 61 .
Statistical analysis. Values were expressed as mean ± s.e. unless otherwise noted. Difference between experimental groups was determined by one-way analysis of variance. Po0.05 was considered statistically significant.
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